Introduction Recent data show that EGFR pathway and its inhibition maintain their role after
progression of disease during EGFR TKI therapy in NSCLCs. We conducted a retrospective …

Improvements in our understanding of the molecular biology of cancer have shifted
management of lung cancer toward molecular-guided, individualized treatment …

Background The purpose of this study was to evaluate the efficacy of afatinib in EGFR-
mutant metastatic NSCLC patients with acquired resistance to erlotinib or gefitinib. Materials …

BACKGROUND Bone metastasis occurs frequently in advanced prostate cancer (PCa)
patients; however, it is not known why this happens. The epidermal growth factor receptor …

Objective: Salvage treatment for acquired resistance to gefitinib has yet to be developed. We
conducted the first prospective phase II study of gefitinib readministration in previous …

Non-Small-Cell Lung Cancer (NSCLC) with somatic mutations of the epidermal growth
factor receptor (EGFR) is anticipated to respond to small-molecule tyrosine kinase inhibitors …

This study investigated the curative effect of cryoablation combined with molecular target
therapy for advanced non-small cell lung cancer (NSCLC). Thirty-six female patients with …

Objective: Accumulated evidence suggests that ATP-binding cassette A1 transporter
(ABCA1) contributes to secreting insulin in pancreatic β-cells and amyloid beta formation …

Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such
as gefitinib can provide better efficacy and prolonged progression free survival (PFS) than …

Since the first description of non-small cell lung cancer (NSCLC) with activating epidermal
growth factor receptor (EGFR) mutation as a distinct clinical entity, studies have proved …